Novamind Partners with Merck for New Treatment-Resistant Depression Trial

• Wholly-owned subsidiary, Cedar Clinical Research selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co. a world-leading pharmaceutical company
• Phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder

Why Novamind?

• Building the infrastructure required for a regulated psychedelics industry
• Rapidly expanding a network of outpatient mental health clinics and research sites
• Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
  • Ketamine treatment volume grew 90% from 2019 to 2020
  • During the same period, total Spravato™ treatments rose 400%
• Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
• Specializing in psychedelic-assisted treatment protocols
• Building centers of excellence for future approved psychedelic treatments
• Biopharma partnerships with Johnson & Johnson (Janssen Spravato trials) and Merck for New Treatment-Resistant Depression Trial
• $1.29 million in fiscal second quarter revenue
• Strong insider ownership (32.3%)

Watch Our Recent Interview

Novamind is focused on 3 pillars:

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.